Indicator type	Main activity, secondary activity or tool required for...	Total
Companies carrying out R&D in Biotechnology	Total	1.444
Companies carrying out R&D in Biotechnology	Main	629
Companies carrying out R&D in Biotechnology	Secondary	262
Companies carrying out R&D in Biotechnology	Tool required	553
% Companies by type of biotechnology used: Genetic Code	Total	30,7
% Companies by type of biotechnology used: Genetic Code	Main	39,9
% Companies by type of biotechnology used: Genetic Code	Secondary	25,7
% Companies by type of biotechnology used: Genetic Code	Tool required	22,5
% Companies by type of biotechnology used: Functional Units	Total	37,6
% Companies by type of biotechnology used: Functional Units	Main	46,4
% Companies by type of biotechnology used: Functional Units	Secondary	39,8
% Companies by type of biotechnology used: Functional Units	Tool required	26,5
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Total	21,3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Main	26,3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Secondary	20
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Tool required	16,2
% Companies by type of biotechnology used: Bioprocesses	Total	50,9
% Companies by type of biotechnology used: Bioprocesses	Main	42,3
% Companies by type of biotechnology used: Bioprocesses	Secondary	57
% Companies by type of biotechnology used: Bioprocesses	Tool required	58
% Companies by type of biotechnology used: Subcellular Organisms	Total	8,1
% Companies by type of biotechnology used: Subcellular Organisms	Main	11,6
% Companies by type of biotechnology used: Subcellular Organisms	Secondary	5,5
% Companies by type of biotechnology used: Subcellular Organisms	Tool required	5,2
% Companies by type of biotechnology used: Bioinformatics	Total	22,6
% Companies by type of biotechnology used: Bioinformatics	Main	32,3
% Companies by type of biotechnology used: Bioinformatics	Secondary	21
% Companies by type of biotechnology used: Bioinformatics	Tool required	12,5
% Companies by type of biotechnology used: Nanobiotechnology	Total	9,8
% Companies by type of biotechnology used: Nanobiotechnology	Main	14,5
% Companies by type of biotechnology used: Nanobiotechnology	Secondary	10,1
% Companies by type of biotechnology used: Nanobiotechnology	Tool required	4,4
% Companies by type of biotechnology used: Other	Total	16,9
% Companies by type of biotechnology used: Other	Main	18,1
% Companies by type of biotechnology used: Other	Secondary	19,5
% Companies by type of biotechnology used: Other	Tool required	14,2
% Companies by final application areas of biotechnology use: Human Health	Total	44,3
% Companies by final application areas of biotechnology use: Human Health	Main	65
% Companies by final application areas of biotechnology use: Human Health	Secondary	33,6
% Companies by final application areas of biotechnology use: Human Health	Tool required	25,9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Total	15,8
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Main	16,9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Secondary	18
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Tool required	13,5
% Companies by final application areas of biotechnology use: Food Products	Total	30,7
% Companies by final application areas of biotechnology use: Food Products	Main	24,8
% Companies by final application areas of biotechnology use: Food Products	Secondary	30,6
% Companies by final application areas of biotechnology use: Food Products	Tool required	37,5
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Total	24,9
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Main	21,3
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Secondary	28,7
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Tool required	27,3
% Companies by final application areas of biotechnology use: Environment	Total	16,9
% Companies by final application areas of biotechnology use: Environment	Main	17,9
% Companies by final application areas of biotechnology use: Environment	Secondary	20,5
% Companies by final application areas of biotechnology use: Environment	Tool required	14,2
% Companies by final application areas of biotechnology use: Industry	Total	12,6
% Companies by final application areas of biotechnology use: Industry	Main	13,1
% Companies by final application areas of biotechnology use: Industry	Secondary	15,9
% Companies by final application areas of biotechnology use: Industry	Tool required	10,4
R&D personnel in Biotechnology (PP)	Total	17.743
R&D personnel in Biotechnology (PP)	Main	8.842
R&D personnel in Biotechnology (PP)	Secondary	3.407
R&D personnel in Biotechnology (PP)	Tool required	5.494
R&D personnel in Biotechnology (PP): Research personnel	Total	9.445
R&D personnel in Biotechnology (PP): Research personnel	Main	5.239
R&D personnel in Biotechnology (PP): Research personnel	Secondary	1.814
R&D personnel in Biotechnology (PP): Research personnel	Tool required	2.392
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Total	8.298
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Main	3.603
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Secondary	1.594
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Tool required	3.101
R&D personnel in Biotechnology (PP). Women	Total	9.907
R&D personnel in Biotechnology (PP). Women	Main	5.154
R&D personnel in Biotechnology (PP). Women	Secondary	1.970
R&D personnel in Biotechnology (PP). Women	Tool required	2.782
R&D personnel in Biotechnology (PP). Women: Research personnel	Total	5.104
R&D personnel in Biotechnology (PP). Women: Research personnel	Main	2.942
R&D personnel in Biotechnology (PP). Women: Research personnel	Secondary	1.011
R&D personnel in Biotechnology (PP). Women: Research personnel	Tool required	1.151
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Total	4.802
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Main	2.212
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Secondary	959
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Tool required	1.632
R&D personnel in Biotechnology (FTE)	Total	12.993,4
R&D personnel in Biotechnology (FTE)	Main	7.060,1
R&D personnel in Biotechnology (FTE)	Secondary	2.147,6
R&D personnel in Biotechnology (FTE)	Tool required	3.785,7
R&D personnel in Biotechnology (FTE): Research personnel	Total	7.069,9
R&D personnel in Biotechnology (FTE): Research personnel	Main	4.263,3
R&D personnel in Biotechnology (FTE): Research personnel	Secondary	1.145,5
R&D personnel in Biotechnology (FTE): Research personnel	Tool required	1.661,1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Total	5.923,6
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Main	2.796,8
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Secondary	1.002,1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Tool required	2.124,7
R&D personnel in Biotechnology (FTE). Women	Total	7.471,8
R&D personnel in Biotechnology (FTE). Women	Main	4.169,3
R&D personnel in Biotechnology (FTE). Women	Secondary	1.295,3
R&D personnel in Biotechnology (FTE). Women	Tool required	2.007,3
R&D personnel in Biotechnology (FTE). Women: Research personnel	Total	3.870,1
R&D personnel in Biotechnology (FTE). Women: Research personnel	Main	2.420,4
R&D personnel in Biotechnology (FTE). Women: Research personnel	Secondary	630,8
R&D personnel in Biotechnology (FTE). Women: Research personnel	Tool required	819
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Total	3.601,6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Main	1.748,9
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Secondary	664,5
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Tool required	1.188,2
Expenditure on internal R&D in Biotechnology (thousands of euros)	Total	1.223.801
Expenditure on internal R&D in Biotechnology (thousands of euros)	Main	670.507
Expenditure on internal R&D in Biotechnology (thousands of euros)	Secondary	216.401
Expenditure on internal R&D in Biotechnology (thousands of euros)	Tool required	336.893
1) By type of expenditure: Current expenditure	Total	1.108.189
1) By type of expenditure: Current expenditure	Main	604.206
1) By type of expenditure: Current expenditure	Secondary	191.555
1) By type of expenditure: Current expenditure	Tool required	312.429
1.1) Labour expenditure of research personnel	Total	360.922
1.1) Labour expenditure of research personnel	Main	207.759
1.1) Labour expenditure of research personnel	Secondary	64.211
1.1) Labour expenditure of research personnel	Tool required	88.953
1.2) Labour expenditure of technical and auxiliary personnel	Total	220.540
1.2) Labour expenditure of technical and auxiliary personnel	Main	104.553
1.2) Labour expenditure of technical and auxiliary personnel	Secondary	29.638
1.2) Labour expenditure of technical and auxiliary personnel	Tool required	86.349
1.3) Other current expenditure	Total	526.727
1.3) Other current expenditure	Main	291.895
1.3) Other current expenditure	Secondary	97.706
1.3) Other current expenditure	Tool required	137.126
2) By type of expenditure: Capital expenditure	Total	115.612
2) By type of expenditure: Capital expenditure	Main	66.301
2) By type of expenditure: Capital expenditure	Secondary	24.847
2) By type of expenditure: Capital expenditure	Tool required	24.464
2.1) Land and buildings	Total	16.843
2.1) Land and buildings	Main	12.566
2.1) Land and buildings	Secondary	799
2.1) Land and buildings	Tool required	3.478
2.2) Equipment and tools	Total	63.527
2.2) Equipment and tools	Main	33.190
2.2) Equipment and tools	Secondary	12.906
2.2) Equipment and tools	Tool required	17.431
2.3) Acquisition of specific R&D software	Total	3.959
2.3) Acquisition of specific R&D software	Main	2.511
2.3) Acquisition of specific R&D software	Secondary	548
2.3) Acquisition of specific R&D software	Tool required	900
2.4) Other R&D-specific IP products	Total	31.284
2.4) Other R&D-specific IP products	Main	18.033
2.4) Other R&D-specific IP products	Secondary	10.594
2.4) Other R&D-specific IP products	Tool required	2.656
1.1) By origin of funds: Own funds	Total	860.603
1.1) By origin of funds: Own funds	Main	442.509
1.1) By origin of funds: Own funds	Secondary	148.111
1.1) By origin of funds: Own funds	Tool required	269.983
1.2) By origin of funds: Funds from the Business sector	Total	128.002
1.2) By origin of funds: Funds from the Business sector	Main	86.860
1.2) By origin of funds: Funds from the Business sector	Secondary	21.937
1.2) By origin of funds: Funds from the Business sector	Tool required	19.205
1.3) By origin of funds: Funds from the Public Administration sector	Total	119.498
1.3) By origin of funds: Funds from the Public Administration sector	Main	69.092
1.3) By origin of funds: Funds from the Public Administration sector	Secondary	24.659
1.3) By origin of funds: Funds from the Public Administration sector	Tool required	25.748
1.4) By origin of funds: Funds from the Higher Education sector	Total	647
1.4) By origin of funds: Funds from the Higher Education sector	Main	620
1.4) By origin of funds: Funds from the Higher Education sector	Secondary	0
1.4) By origin of funds: Funds from the Higher Education sector	Tool required	28
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Total	12.986
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Main	9.058
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Secondary	0
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Tool required	3.927
1.6) By origin of funds: Funds from the rest of the world	Total	102.065
1.6) By origin of funds: Funds from the rest of the world	Main	62.369
1.6) By origin of funds: Funds from the rest of the world	Secondary	21.694
1.6) By origin of funds: Funds from the rest of the world	Tool required	18.002
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Total	123.396
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Main	113.418
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Secondary	5.801
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Tool required	4.177
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Total	88.985
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Main	80.703
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Secondary	4.777
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Tool required	3.505
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Total	34.412
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Main	32.714
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Secondary	1.024
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Tool required	673
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Total	39,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Main	50,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Secondary	36,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Tool required	29,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Total	15,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Main	13,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Secondary	19,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Tool required	15,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Total	22,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Main	24
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Secondary	21,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Tool required	20,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Total	12,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Main	10,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Secondary	15,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Tool required	11,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Total	17,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Main	17,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Secondary	21,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Tool required	14,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Total	17,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Main	20,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Secondary	20,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Tool required	13,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Total	16
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Main	17,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Secondary	18,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Tool required	12,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Total	41,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Main	46,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Secondary	41,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Tool required	35,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Total	50,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Main	57,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Secondary	50,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Tool required	42
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Total	20,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Main	21,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Secondary	22,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Tool required	17
% Companies with international revenues related to biotechnology activities	Total	22,7
% Companies with international revenues related to biotechnology activities	Main	30,6
% Companies with international revenues related to biotechnology activities	Secondary	21,8
% Companies with international revenues related to biotechnology activities	Tool required	14,2
% Companies representing international revenues related to biotechnology activities	Total	2,1
% Companies representing international revenues related to biotechnology activities	Main	13,2
% Companies representing international revenues related to biotechnology activities	Secondary	0,4
% Companies representing international revenues related to biotechnology activities	Tool required	2,2
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Total	60,6
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Main	62,9
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Secondary	52,4
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Tool required	59,7
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Total	39,4
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Main	37,1
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Secondary	47,6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Tool required	40,3
% International revenues related to biotechnology activities by classification: International trade in goods and services	Total	87,8
% International revenues related to biotechnology activities by classification: International trade in goods and services	Main	79,4
% International revenues related to biotechnology activities by classification: International trade in goods and services	Secondary	98
% International revenues related to biotechnology activities by classification: International trade in goods and services	Tool required	99,1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total	10,1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Main	17,6
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Secondary	0
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Tool required	0
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Total	1,4
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Main	1,7
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Secondary	2
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Tool required	0,7
% International revenues related to biotechnology activities by classification: Other	Total	0,8
% International revenues related to biotechnology activities by classification: Other	Main	1,2
% International revenues related to biotechnology activities by classification: Other	Secondary	0
% International revenues related to biotechnology activities by classification: Other	Tool required	0,2